VERAXA Biotech AG (NASDAQ: VRXA) is making strides in the oncology therapeutics space, focusing on the discovery and development of a new generation of antibody-based treatments for solid tumors. The company's vision is to deliver the next wave of smart cancer therapies with curative potential and improved safety profiles, according to a recent article highlighting the company as 'one to watch'.
VERAXA is building a pipeline that includes dual-targeting antibody-drug conjugates (ADCs) and T-cell engagers (TCEs), predominantly based on its patented BiTAC concept. This concept is designed to improve the precision, safety, and effectiveness of cancer treatments. By focusing on potentially first-in-class conditionally active ADC and TCE platforms, VERAXA is positioned within two rapidly growing segments of the global oncology therapeutics market.
The company's pipeline spans multiple formats, including monoclonal antibodies, antibody-drug conjugates, bispecific ADCs, and proprietary BiTAC-based therapeutic formats. VERAXA was founded on scientific breakthroughs made at the European Molecular Biology Laboratory, a world-renowned institution known for pioneering life science research and cutting-edge technology.
VERAXA is rapidly advancing its pipeline of ADCs and proprietary BiTAC formats into clinical development and beyond. The company is building a premier engine for the discovery and development of next-generation antibody-based therapeutics, powered by a suite of transformative technologies and guided by rigorous quality-by-design principles.
For investors, the latest news and updates relating to VRXA are available in the company's newsroom at https://ibn.fm/VRXA. To view the full article on VERAXA, visit https://ibn.fm/9jQnNA.
